Patents by Inventor Demetrios P. Papahadjopoulos

Demetrios P. Papahadjopoulos has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7871620
    Abstract: The present invention provides for immunoliposomes that optimizes internalization of a drug into target cells bearing a characteristic cell surface marker. The immunoliposomes comprise an Fab? domain of an antibody that specifically binds the characteristic marker, an amphipathic vesicle-forming lipid, and a polyethylene glycol derivatized lipid. The invention also provides for growth-inhibiting immunoliposomes that lack growth-inhibiting therapeutic agents and yet are capable of inhibiting the growth and proliferation of target cells.
    Type: Grant
    Filed: February 12, 2009
    Date of Patent: January 18, 2011
    Assignee: The Regents of the University of California
    Inventors: Christopher C. Benz, Demetrios P. Papahadjopoulos, Francis C. Szoka, legal representative, John W. Park, Keelung Hong, Dmitri Kirpotin
  • Patent number: 7507407
    Abstract: The present invention provides for immunoliposomes that optimizes internalization of a drug into target cells bearing a characteristic cell surface marker. The immunoliposomes comprise an Fab? domain of an antibody that specifically binds the characteristic marker, an amphipathic vesicle-forming lipid, and a polyethylene glycol derivatized lipid. The invention also provides for growth-inhibiting immunoliposomes that lack growth-inhibiting therapeutic agents and yet are capable of inhibiting the growth and proliferation of target cells.
    Type: Grant
    Filed: October 11, 2006
    Date of Patent: March 24, 2009
    Assignee: The Regents of the University of California
    Inventors: Christopher C. Benz, Demetrios P. Papahadjopoulos, John W. Park, Keelung Hong, Dmitri Kirpotin
  • Patent number: 6214388
    Abstract: The present invention provides for immunoliposomes that optimizes internalization of a drug into target cells bearing a characteristic cell surface marker. The immunoliposomes comprise an Fab′ domain of an antibody that specifically binds the characteristic marker, an amphipathic vesicle-forming lipid, and a polyethylene glycol derivatized lipid. The invention also provides for growth-inhibiting immunoliposomes that lack growth-inhibiting therapeutic agents and yet are capable of inhibiting the growth and proliferation of target cells.
    Type: Grant
    Filed: April 18, 1996
    Date of Patent: April 10, 2001
    Assignee: The Regents of the University of California
    Inventors: Christopher C. Benz, Demetrios P. Papahadjopoulos, John W. Park, Keelung Hong, Dmitri Kirpotin
  • Patent number: 4806466
    Abstract: A number of naturally occurring antibodies to human erythrocyte surface antigens are capable of combining with their specific antigens (for example, Rhesus factor), but are not capable of producing visible hemagglutination. Also, the sensitivity of many diagnostic methods, such as in human blood typing, depends upon cell agglutination.The present invention provides liposome-protein conjugates, especially useful for hemagglutination assays, having an enhanced agglutination capacity with respect to antibody from which the conjugates are derived.
    Type: Grant
    Filed: March 17, 1986
    Date of Patent: February 21, 1989
    Assignee: The Regents of the University of California
    Inventors: Demetrios P. Papahadjopoulos, Timothy D. Heath
  • Patent number: 4598051
    Abstract: A number of naturally occurring antibodies to human erythrocyte surface antigens are capable of combining with their specific antigens (for example, Rhesus factor), but are not capable of producing visible hemagglutination. Also, the sensitivity of many diagnostic methods, such as in human blood typing, depends upon cell agglutination.The present invention provides liposome-protein conjugates, especially useful for hemagglutination assays, having an enhanced agglutination capacity with respect to antibody fromThe invention described herein was made in the course of work under a grant or award from the Department of Health and Human Services.
    Type: Grant
    Filed: October 29, 1981
    Date of Patent: July 1, 1986
    Assignee: The Regents of the University of California
    Inventors: Demetrios P. Papahadjopoulos, Timothy D. Heath
  • Patent number: 4429008
    Abstract: Liposomes are provided which have a plurality of thiol reactive groups extending outward of the liposomal bilayer. The liposomes form stable covalent bonds with ligands having thiol groups, such as Fab' fragments. Particularly preferred liposomes include maleimide moieties as the thiol reactive groups. The thiol reactive liposomes are usefully employed in agglutination assays, such as blood typing and binding inhibitions, and targeting to specific cells.
    Type: Grant
    Filed: December 10, 1981
    Date of Patent: January 31, 1984
    Assignee: The Regents of the University of California
    Inventors: Frank J. Martin, Demetrios P. Papahadjopoulos, Wayne L. Hubbell
  • Patent number: 4394149
    Abstract: The disclosure is of the use of plant nutriments encapsulated in synthetic lipid vesicles to nourish plants. SPCROSS-REFERENCE TO RELATED APPLICATIONThis application is a Continuation-in-Part of our copending application Ser. No. 881,116 filed Feb. 24, 1978 and now U.S. Pat. No. 4,235,871.
    Type: Grant
    Filed: May 13, 1980
    Date of Patent: July 19, 1983
    Inventors: Francis C. Szoka, Jr., Demetrios P. Papahadjopoulos
  • Patent number: 4394448
    Abstract: A method of inserting deoxyribonucleic acid or fragments thereof into a living cell, which comprises; encapsulating the DNA or fragment in a lipid vesicle and bringing the vesicle in contact with said cell, whereby insertion occurs.
    Type: Grant
    Filed: April 24, 1980
    Date of Patent: July 19, 1983
    Inventors: Francis C. Szoka, Jr., Demetrios P. Papahadjopoulos
  • Patent number: 4241046
    Abstract: The disclosure is of a method for encapsulating biologically active materials in synthetic, oligolamellar lipid vesicles (liposomes). The method comprises providing a mixture of lipid in organic solvent and an aqueous mixture of the material for encapsulation, emulsifying the provided mixture, removing the organic solvent and suspending the resultant gel in water. The method of the invention is advantageous over prior art methods of encapsulating biologically active materials in that it provides a means for a relatively high capture efficiency of the material for encapsulation. The disclosure is also of intermediate compositions in the encapsulation method, the product vesicles, compositions including the product vesicles as an active ingredient and their use.
    Type: Grant
    Filed: November 30, 1978
    Date of Patent: December 23, 1980
    Inventors: Demetrios P. Papahadjopoulos, Francis C. Szoka, Jr.
  • Patent number: 4235871
    Abstract: The disclosure is of a method for encapsulating biologically active materials in synthetic, oligolamellar lipid vesicles (liposomes). The method comprises providing a mixture of lipid in organic solvent and an aqueous mixture of the material for encapsulation, emulsifying the provided mixture, removing the organic solvent and suspending the resultant gel in water. The method of the invention is advantageous over prior art methods of encapsulating biologically active materials in that it provides a means for a relatively high capture efficiency of the material for encapsulation. The disclosure is also of intermediate compositions in the encapsulation method, the product vesicles, compositions including the product vesicles as an active ingredient and their use.
    Type: Grant
    Filed: February 24, 1978
    Date of Patent: November 25, 1980
    Inventors: Demetrios P. Papahadjopoulos, Francis C. Szoka, Jr.